---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-077895"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T21:58:57.725498+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Synlogic Q4 2021 net loss $15.1M; cash $136.6M; PKU Phase 3 on track for H2 2022

## Summary
- Q4 2021 net loss $15.1M ($0.21/share) vs $14.6M ($0.39/share) in Q4 2020; FY 2021 net loss $60.6M ($1.09/share).
- Cash, equivalents & marketable securities $136.6M at Dec 31, 2021; projected runway into 2024.
- PKU program: Phase 2 SynPheny-1 data expected H1 2022; Phase 3 trial initiation planned H2 2022.
- Appointed Michael Jensen as CFO in March 2022; he was formerly CFO of Intrinsic Therapeutics.
- HCU candidate SYNB1353 IND submission and Phase 1 healthy volunteer data expected H2 2022.

## SEC filing metadata
- accession: 0001193125-22-077895
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000119312522077895/0001193125-22-077895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000119312522077895/d284910d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-077895
- JSON: https://secwatch.observer/filing/0001193125-22-077895.json
- Plain text: https://secwatch.observer/filing/0001193125-22-077895.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.